Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of VDT (velcade, Doxil and thalidomide) [bortezomib + doxorubicin liposomal + thalidomide] as frontline therapy for patients with previously untreated multiple myeloma (MM).

Next Previous
X
Search
Trial Profile

Phase II study of VDT (velcade, Doxil and thalidomide) [bortezomib + doxorubicin liposomal + thalidomide] as frontline therapy for patients with previously untreated multiple myeloma (MM).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin liposomal (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Feb 2009 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 11 Dec 2007 Results will be presented at the 49th annual meeting of the American Society of Hematology.
    • 07 Sep 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top